ReviewFrontiers in bioengineering and biotechnology2025
Recent progress of nanomaterials for diagnosis and treatment of rejection in heart transplantation.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transplant rejection and the side effects of immunosuppressive therapy have hindered heart transplantation development. Rejection of a heart transplant can lead to cellular and antibody-mediated immunoinflammatory responses and allograft dysfunction, thereby significantly affecting patients' survival and prognosis. To address these challenges, many new technologies and materials, including nanomaterials, have been developed for potential applications in the heart transplantation field. Nanomaterials are most commonly used as drug delivery carriers, and the addition of specific ligands can enhance drug utilization, strengthen therapeutic effects, and reduce the occurrence of adverse reactions. In addition, nanomaterials have been developed as targeted molecular probes to support various imaging techniques and to assist in monitoring the infiltration of immune cells (such as T cells and macrophages) into cardiac tissue, thus facilitating the early diagnosis of acute rejection (AR). Continuous advances in nanotechnology have led to the development of "theranostic" and intelligent-response nanomaterials for precise disease diagnosis and simultaneous treatment. Nanomedicine primarily relies on the development of Nanomaterials and nanostructured surfaces, along with the application of nanotechnology, for molecular diagnosis, therapy, monitoring, and disease treatment. In this review, we examine the recent development of nanomaterials for the diagnosis and treatment of AR in heart transplantation, and discuss the challenges and future directions for the clinical translation of nanomaterials in heart transplantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.